Indoco Remedies (NSE:INDOCO) Cyclically Adjusted Revenue per Share: ₹184.96 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:INDOCO Indoco Remedies Ltd NSE:INDOCO
67 GF Score
Price ₹223.58
GF Value ₹342.95
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Indoco Remedies Cyclically Adjusted Revenue per Share?

Indoco Remedies NSE:INDOCO +0.82% 67 Cyclically Adjusted Revenue per Share is ₹184.96 as of Jun. 2026. GuruFocus rates NSE:INDOCO with a GF Score™ of 67/100 and a GF Value™ of ₹342.95 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Indoco Remedies's adjusted revenue per share for the three months ended in Jun. 2026 was ₹50.862. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹184.96 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Indoco Remedies's average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-05), Indoco Remedies's current stock price is ₹223.58. Indoco Remedies's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹184.96. Indoco Remedies's Cyclically Adjusted PS Ratio of today is 1.21.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Indoco Remedies was 2.24. The lowest was 0.96. And the median was 1.48.


Indoco Remedies  (NSE:INDOCO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Indoco Remedies's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=223.58/184.96
=1.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Indoco Remedies was 2.24. The lowest was 0.96. And the median was 1.48.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Indoco Remedies Cyclically Adjusted Revenue per Share Related Terms


Indoco Remedies Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Indoco Remedies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indoco Remedies Cyclically Adjusted Revenue per Share Chart

Indoco Remedies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 170.84 181.23

Indoco Remedies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 174.97 178.33 179.88 181.23 184.96

NSE:INDOCO vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indoco Remedies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indoco Remedies Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indoco Remedies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Indoco Remedies's Cyclically Adjusted PS Ratio falls into.


NSE:INDOCO
67GF Score
Indoco Remedies Ltd NSE:INDOCO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indoco Remedies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Indoco Remedies's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=50.862/166.1454*166.1454
=50.862

Current CPI (Jun. 2026) = 166.1454.

Indoco Remedies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201306 16.772 88.365 31.535
201403 0.000 91.425 0.000
201406 21.508 94.103 37.974
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 23.039 111.317 34.387
201809 25.687 115.142 37.065
201812 26.831 115.142 38.716
201903 28.335 118.202 39.828
201906 26.722 120.880 36.729
201909 31.150 123.175 42.017
201912 30.837 126.235 40.586
202003 28.380 124.705 37.811
202006 28.966 127.000 37.894
202009 35.013 130.118 44.708
202012 36.182 130.889 45.928
202103 32.085 131.771 40.455
202106 41.355 134.084 51.243
202109 40.432 135.847 49.450
202112 37.859 138.161 45.527
202203 43.454 138.822 52.007
202206 42.933 142.347 50.111
202209 43.972 144.661 50.502
202212 44.547 145.763 50.776
202303 46.492 146.865 52.596
202306 44.774 150.280 49.501
202309 51.392 151.492 56.363
202312 47.564 152.924 51.676
202403 49.081 153.035 53.286
202406 46.043 155.789 49.104
202409 49.051 157.882 51.618
202412 46.970 158.323 49.291
202503 42.581 157.552 44.904
202506 47.432 159.755 49.329
202509 59.499 162.289 60.913
202512 46.656 163.281 47.475
202603 54.144 164.272 54.761
202606 50.862 166.145 50.862

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹184.96 mean?
Indoco Remedies (NSE:INDOCO) has a Cyclically Adjusted Revenue per Share of ₹184.96 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Indoco Remedies and its competitors.
Is Indoco Remedies' Cyclically Adjusted Revenue per Share too high?
Indoco Remedies' current Cyclically Adjusted Revenue per Share is ₹184.96. Overall, Indoco Remedies has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indoco Remedies' Cyclically Adjusted Revenue per Share compare to ZTS?
Indoco Remedies' Cyclically Adjusted Revenue per Share of ₹184.96 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Indoco Remedies and its competitors. Indoco Remedies's current Cyclically Adjusted Revenue per Share is ₹184.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indoco Remedies stock overvalued right now?
Based on GuruFocus' analysis, Indoco Remedies (NSE:INDOCO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹342.95, compared to a current price of ₹223.58 — trading 34.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹184.96. Indoco Remedies' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Indoco Remedies (NSE:INDOCO), the current Cyclically Adjusted Revenue per Share is ₹184.96 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indoco Remedies (NSE:INDOCO) Overvalued in 2026?

Based on GuruFocus' analysis, Indoco Remedies stock appears to be undervalued. The current stock price of ₹223.58 is trading 34.8% below its estimated GF Value™ of ₹342.95. GuruFocus considers Indoco Remedies to be Possible Value Trap.

Key valuation signals for NSE:INDOCO:

  • Cyclically Adjusted Revenue per Share: ₹184.96
  • GF Value™: ₹342.95 vs. price of ₹223.58 (34.8% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the NSE:INDOCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Indoco Remedies Business Description

Other Exchanges 532612:India
Address 166 CST Road, Indoco House, Kalina, Santacruz (East), Mumbai, MH, IND, 400 098
Indoco Remedies Ltd is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company manufactures products for different therapeutic sectors including Gastroenterology, Dentistry & Stomatology, Respiratory, Diabetology, Women's Health, Nutritional products, Cardiology, Metabolic Disorders, and Primary Care medicines. The only operating segment of the company is Pharmaceutical Products. Geographically, it generates the majority of the revenue from India.
67GF Score

Get the complete analysis for NSE:INDOCO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹223.58
Price
₹342.95
GF Value